Skip to content
10-Q

Quarterly Report

Dicerna Pharmaceuticals Inc

0001399529-20-000089

← back to feed
Filed
Nov 5, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Nov 2, 2020 75.04M sh
Current Liabilities Q3 2020 · Sep 30, 2020 $239.77M
Current Liabilities Q3 2020 · Dec 31, 2019 $241.74M
Total Liabilities Q3 2020 · Sep 30, 2020 $528.04M
Total Liabilities Q3 2020 · Dec 31, 2019 $445.21M
Current Assets Q3 2020 · Sep 30, 2020 $627.65M
Current Assets Q3 2020 · Dec 31, 2019 $556.17M
Total Assets Q3 2020 · Sep 30, 2020 $681.74M
Total Assets Q3 2020 · Dec 31, 2019 $597.41M
Cash And Equivalents Q3 2020 · Dec 31, 2019 $152.82M
Cash And Equivalents Q3 2020 · Sep 30, 2019 $47.23M
Capex Q3 2020 · Sep 30, 2019 $5.31M
Operating Cash Flow Q3 2020 · Sep 30, 2019 $14.23M
Stockholders Equity Q3 2020 · Sep 30, 2019 $134.37M
Stockholders Equity Q3 2020 · Jun 30, 2019 $160.17M
Stockholders Equity Q3 2020 · Mar 31, 2019 $179.63M
Stockholders Equity Q3 2020 · Dec 31, 2018 $200.69M
Sga Expense Q3 2020 · Sep 30, 2019 $10.62M
Sga Expense Q3 2020 · Sep 30, 2019 $29.13M
Rd Expense Q3 2020 · Sep 30, 2019 $30.09M
Rd Expense Q3 2020 · Sep 30, 2019 $74.52M
Net Income Q3 2020 · Sep 30, 2019 −$30.79M
Net Income Q3 2020 · Sep 30, 2019 −$80.79M
Net Income Q3 2020 · Jun 30, 2019 −$23.85M
Net Income Q3 2020 · Mar 31, 2019 −$26.15M
Operating Income Q3 2020 · Sep 30, 2019 −$32.67M
Operating Income Q3 2020 · Sep 30, 2019 −$86.82M
Revenue Q3 2020 · Sep 30, 2019 $8.04M
Revenue Q3 2020 · Sep 30, 2019 $16.82M